NCT05843253 2026-04-22
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
Clinical Trials
12 trialsNCT07462507 2026-04-21
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Washington University School of Medicine
Phase 2 Recruiting
NCT02800486 2026-04-13
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
Northwell Health
Phase 2 Recruiting
NCT07301268 2026-04-08
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
Mayo Clinic
Phase 2 Recruiting
NCT07417761 2026-04-02
TUVASTRAT
Grupo Español de Investigación en Neurooncología
Phase 2 Recruiting
NCT05345002 2026-02-20
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT05683808 2026-01-30
VTE-POG
University of Vermont Medical Center
Phase 2 Recruiting
NCT04623931 2026-01-14
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06776250 2025-09-19
Study of How Safe and Effective Tarlatamab is in Brain Cancers
University Health Network, Toronto
Phase 2 Recruiting
NCT05180825 2025-08-08
PLGG - MEKTRIC
University Hospital, Strasbourg, France
Phase 2 Recruiting
NCT06264388 2025-05-29
DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
University of Miami
Phase 2 Recruiting
NCT06161974 2025-02-21
Study of Olutasidenib and Temozolomide in HGG
Rigel Pharmaceuticals
Phase 2 Recruiting